Last reviewed · How we verify
NCT06549946: IXACT
Ixovex-1 Single Agent and Combination Therapy
Phase 1, PHASE2 trial testing Ixovex-1 in Solid Tumor in 18 participants. Currently enrolling.
30 January 2027
Quick facts
| Lead sponsor | Psivac Ltd |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 17 December 2024 |
| Primary completion | 30 January 2027 |
| Estimated completion | 30 January 2027 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Ixovex-1 — full drug profile →
- Pembrolizumab (pembrolizumab) — full drug profile →
Conditions studied
- Solid Tumor — all drugs for Solid Tumor →
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
Sponsor
Psivac Ltd — full company profile →
Who can join
18 and older, any sex, with Solid Tumor or Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, dose de-escalating, non-randomised, multi-centre phase I/II study to determine safety and efficacy of the oncolytic virus, Ixovex-1 administered by intratumoural (IT) injection. This will be assessed in patients with palpable locally advanced, unresectable, or metastatic tumours, for whom all approved therapeutic options have been exhausted, are not available, are unlikely to have significant clinical benefit, or are declined by the patient.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Oncolytic viruses in head and neck cancers: clinical applications and therapeutic potential.
Gupta A, Chavan SR, Gadepalli R, Pareek P. · · 2025 · cited 1× · PMID 40881284 · DOI 10.3389/fmicb.2025.1641267
Verify or expand the search:
- PubMed search for NCT06549946
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor
Currently open trials in the same condition.
- NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
- NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
- NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06549946 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Psivac Ltd
- Last refreshed: 30 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06549946.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing